Introduction {#S0001}
============

Vestibular schwannoma (VS), also called acoustic neuroma, is a benign tumor arising from Schwann cells of the vestibular portion of the eighth cranial nerve inside the internal auditory canal. With tumor growth it fills the internal auditory canal and extends beyond it, reaching the cerebellopontine angle region. The most common symptoms of VS occurrence are progressive deterioration of hearing, dizziness and headache. The progression of the tumor to nerve V leads to facial paresthesia. When the tumor reaches nerves IX, X, and XI there are difficulties in swallowing. Compression of the brain stem by the tumor leads to an imbalance and sometimes hydrocephalus. The incidence of these tumors is estimated at one in 100 000 people a year, but recently in connection with the frequent use of magnetic resonance imaging (MRI) detection of VS is twice as high \[[@CIT0001], [@CIT0002]\].

One of the alternative methods of surgical treatment of VS is Gamma Knife radiosurgery (GKRS). Clinical experience with proton beam irradiation to the central part of the brain was initiated in the 1960s by Professor Lars Lexell at the Gustaf Werner Institute in Uppsala (Sweden) \[[@CIT0003]\]. In 1967, when this therapeutic tool was used for the first time, the name "Gamma Knife" (GK) was coined. The basic concept of GK was that extremely well-collimated beams from a large number of Cobalt-60 sources, distributed around a half-spherical collimator helmet, would allow a circumscribed focus of beam to be produced in the central part of the patient\'s skull. The initial goal was to offer the use of GK surgery, the traditional non-surgical removal of only some of the lesions, but later it was found that precise irradiation of small intracranial tumors located even in the pituitary gland was possible. Currently, the number of patients treated using the Gamma Knife is estimated at 50 000 a year \[[@CIT0004]\].

Worldwide, there are four models using the Gamma Knife: U/A, B, C/4-C and LGK Perfexion \[[@CIT0005], [@CIT0006]\]. The last model was introduced in 2006. It allows the range of operation to be extended and is equipped with advanced dose planning software, for precise and dynamic beam shaping.

Based on a population of 40 000 000 in Poland it is estimated that about 500 vestibular schwannomas are newly diagnosed each year and most of them are treated by a retrosigmoid approach in general anesthesia in neurosurgery departments. In Poland, the Leksell Gamma Knife Perfexion was installed in 2010 in only one center in Warsaw. To date it has been used for the operation of 320 patients with VS. Due to the relatively short time that has elapsed since the application of GK, there are no data about the effects of this method of treatment over time. The purpose of this study was to analyze the progress in treatment of vestibular schwannoma using Gamma Knife radiosurgery based on data in the literature from the last five years.

Material and methods {#S0002}
====================

Articles published in 2007--2011 were searched using PubMed and Medline search engines and publishers Springer, Elsevier and Kluwer, the database in English, using the keywords "gamma knife", "vestibular schwannoma" and "acoustic neuroma". With over 700 abstracts, to continue the search full texts of the various items of literature that contain all the keywords "gamma knife" and "vestibular schwannoma" and "gamma knife" and "acoustic neuroma" were selected. The collected material, located in 20 scientific journals, comprised case studies, analyses of the work of many years of study at a single center, and review papers. Interesting was the use of new models of Leksell Gamma Knife in the various medical centers. The main criteria for the analysis were patient age, tumor size, dose (Gy), the period from radiosurgery to control, the degree of inhibition of tumor growth, and hearing preservation. Correlations between the investigated characteristics were determined using Microsoft Excel. For statistical calculations comparing the series, nonparametric analysis of variance was used and the following tests: Kruskal-Wallis, Van der Waerden, Kolmogorov-Smirnov test, and median one-way analysis. The level of significance was *p* \< 0.05.

Results {#S0003}
=======

In total, 46 long-term clinical studies covering a period from 3 to 22 years were included \[[@CIT0007]--[@CIT0052]\] ([Table 1](#T0001){ref-type="table"}). The longest observations took place in the following medical centers: Pittsburgh (USA), Marseille (France), Komaki (Japan) and Seoul (Korea). The works used different models of Gamma Knife, depending on the period of study and institutions. The latest model, PFX Leksell Gamma Knife, was used in studies at the University of Verona \[[@CIT0034]\] and Marseille \[[@CIT0042]\], and the 4-C model in the study at the University of Pittsburgh \[[@CIT0012], [@CIT0017], [@CIT0025], [@CIT0035]\], Nijmegen \[[@CIT0031], [@CIT0041]\], Philadelphia \[[@CIT0043]\] and Maastricht \[[@CIT0046], [@CIT0047]\].

###### 

Institution, years of clinical studies and the model of Gamma Knife

  First author, year   Institution[\*](#TF0001){ref-type="table-fn"}   Years of the study   Model of GK[\*\*](#TF0002){ref-type="table-fn"}
  -------------------- ----------------------------------------------- -------------------- -------------------------------------------------
  Chopra, 2007         University of Pittsburgh, USA                   1992--2000           B, C, U
  Iwai, 2007           Osaka City General Hospital, Japaan             1994--2004           DN
  Kim, 2007            Seoul National University, Korea                1997--2001           DN
  Litre, 2007          Timone University, Marseille, France            1992--2003           DN
  Massager, 2007       University of Brussels, Belgium                 2000--2004           C
  Mathieu, 2007        University of Pittsburgh, USA                   1987--2005           U, B, C, 4-C
  Delsanti, 2008       Gamma Knife Center, Marseille, France           1992--2004           DN
  Dewan, 2008          Brown University, USA                           1994--2007           DN
  Iwai, 2008           Osaka City General Hospital, Japan              1994--2003           DN
  Nagano, 2008         Chiba University, Japan                         1998--2006           DN
  Niranjan, 2008       University of Pittsburgh, USA                   1987--2003           B, C, 4-C
  Lasak, 2008          Kansas University, USA                          2003--2007           C
  Shuto, 2008          Yokohama Rosai Hospital, Japan                  1992--2005           B
  Wackym, 2008         Medical College of Wisconsin, USA               2000--2008           B
  Yang, 2008           University Hospital of Goyang, Korea            1998--2004           B, C
  Franzin, 2009        IRCCS San Raffaele, Italy                       2001--2007           C
  Fukuoka, 2009        Hospital of Sapporo, Japan                      1991--2003           DN
  Ganz, 2009           Nasser Institute Shobra, Egypt                  DN                   DN
  Kano, 2009           University of Pittsburgh, USA                   2004--2007           C, 4-C
  Liscak, 2009         Na Homolce Hospital, Prague, Czech Republic     1992--2001           B
  Lobato-Polo, 2009    University of Pittsburgh, USA                   1987--2003           U, B, C,
  Myrseth, 2009        Haukeland University Hospital, Norway           2001--2006           C
  Pollock, 2009        Mayo Clinic, Rochester, USA                     1990--2004           DN
  Tamura, 2009         Timone University, Marseille, France            1992--2003           B, C
  Timmer, 2009         Radbout University, Nijmegen, The Netherlands   2003--2007           4-C
  Yomo, 2009           Timone University, Marseille, France            1992--2007           B, C
  Chung, 2010          Taipei Veterans General Hospital, Taiwan        1993--2009           B, C
  Gerosa, 2010         University of Verona, Italy                     2003--2009           C, PFX
  Kano, 2010           University of Pittsburgh, USA                   1987--2008           U, B, C, 4-C
  Lee, 2010            Taipei Veterans General Hospital, Taiwan        1993--2008           B, C
  Nagano, 2010         Chiba Center, Tokyo, Japan                      1998--2004           B, C
  Nakaya, 2010         University of Pittsburg, USA                    1987--1991           U, B, C
  Regis, 2010          Timone University, Marseille, France            1981--1999           B
  Sharma, 2010         All India Medical Institute, India              1997--2008           B
  Timmer, 2010         Radbout University, Nijmegen, The Netherlands   2003--2007           4-C
  Yomo, 2010           Timone University, Marseille, France            2006--2008           4-C, PFX
  Brown, 2011          University of Pennsylvania, USA                 2006--2009           4-C
  Haque, 2011          Columbia University, New York, USA              1998--2009           DN
  Hasegawa, 2011       Komaki City Hospital, Japan                     1991--2009           DN
  Langenberg, 2011a    Maastricht University, The Netherlands          2002--2009           4-C
  Langenberg, 2011b    Maastricht University, The Netherlands          2002--2009           4-C
  Massager, 2011       Gamma Knife Center, Brussels, Belgium           DN                   C
  Milligan, 2011       Mayo Clinic, Rochester, USA                     1997--2006           DN
  Murphy, 2011a        Cleveland Clinic, USA                           1997--2003           B, C
  Park, 2011           Kyung University of Seoul, Korea                1994--2009           DN
  Yang, 2011           University of Pittsburgh, USA                   1994--2008           DN

Short name

Leksell Gamma Knife, Elekta Instruments, Stockholm, Sweden

DN -- data not available

For further analysis the literature was selected according to data required for the analysis of own studies ([Table 2](#T0002){ref-type="table"}). The total number of patients meeting the criteria for the work selected in 28 articles was 3233 \[[@CIT0007], [@CIT0009], [@CIT0012], [@CIT0015]--[@CIT0017], [@CIT0022], [@CIT0023], [@CIT0025]--[@CIT0027], [@CIT0029], [@CIT0030], [@CIT0033], [@CIT0034], [@CIT0036]--[@CIT0041], [@CIT0043], [@CIT0045], [@CIT0047]--[@CIT0050], [@CIT0052]\]. The described groups of patients ranged from 21 to 444 in size depending on location and duration of the study \[[@CIT0033], [@CIT0036]\]. Average age was 52.6 years. The lowest was 29, and the highest was 68 years \[[@CIT0040], [@CIT0038]\]. Tumor volume varied from 0.17 to 12.6 cm^3^ and on average was 3.9 cm^3^. The Gamma Knife surgery (GKS) radiation dose to the periphery of the tumor was on average 12.4 Gy, but was greater than 13.0 Gy only in one publication \[[@CIT0012]\]. The resulting tumor growth control was achieved in 92.7%, and the preservation of serviceable hearing was on average 66.45% with a mean follow-up of 51.24 months. There was no significant correlation between radiation dose and GKS tumor growth inhibition and hearing preservation. In the overall analysis case studies are not included due to the small database \[[@CIT0053]--[@CIT0058]\].

###### 

Data summary from papers listed

  First author, year   Number of patients   Age (yrs)   Tumor volume (cm^3^)   Margin dose (Gy)   Mean follow-up (months)   Tumor control (%)   Hearing preservation (%)[\*](#TF0003){ref-type="table-fn"}
  -------------------- -------------------- ----------- ---------------------- ------------------ ------------------------- ------------------- ------------------------------------------------------------
  Chopra, 2007         216                  56.5        1.3                    13                 68                        98.3                70.0
  Kim, 2007            59                   48          3.41                   12                 73                        97                  33.3
  Mathieu, 2007        62                   36          5.7                    14.0               53                        85                  48
  Iwai, 2008           25                   48          0.27                   12                 89                        96                  64
  Nagano, 2008         100                  59.1        2.7                    12.2               66                        91                  60
  Niranjan, 2008       96                   54          1.12                   13                 28                        99                  77.5
  Franzin, 2009        50                   54          0.73                   13                 36                        96                  68
  Fukuoka, 2009        152                  54          2.0                    12                 60                        94                  71
  Kano, 2009           77                   52          0.75                   12.5               20                        94.7                71
  Liscak, 2009         351                  56          1.9                    12.5               43                        91                  50
  Lobato-Polo, 2009    55                   35          0.17                   13                 64                        96                  93
  Pollock, 2009        293                  58                                 13                 84                        94                  
  Tamura, 2009         74                   47.5        1.35                   12                 48                        93                  78.4
  Chung, 2010          21                   49.5        17.3                   11.9               66                        90.5                
  Gerosa, 2010         74                   59          2.7                    12.4               50                        96                  72
  Lee, 2010            444                  51.0        4.4                    12.0               35.7                      79.1                
  Nagano, 2010         87                   58.6        2.5                    12.0               90                        89.7                
  Nakaya, 2010         202                  68          3.9                    13                 65                        97                  79
  Regis, 2010          47                   54.4        11.2                                      34.7                      97                  79
  Sharma, 2010         30                   29          3.7                    12.0               26.6                      87.5                66.7
  Timmer, 2010         108                  56          2.721                  11.1                                                             78
  Brown, 2011          53                   56          1\. 12                 12.5               16                        96                  79
  Hasegawa, 2011       117                  52          1.9                    12                 56                        97.5                43
  Langenberg, 2011b    33                   54.8        8.8                    12.6               30.0                      88                  58
  Massager, 2011       203                  53                                 12                 42                        89.7                41.8
  Milligan, 2011       22                   61.0        9.4                    12                 66                        86                  47
  Murphy, 2011a        117                  60.9        1.95                   12.8               37.5                      91.8                85
  Yang, 2011           65                   51          9                                         36                        93                  82
  **Total**            **3233**                                                                                                                 
  **Mean**                                  **52.6**    **3.90**               **12.40**          **51.24**                 **92.73**           **66.45**

Empty data fields are from data that were not reported, not accessible, or could not be disaggregated for analysis in this study.

Hearing preservation in grade I-II according to Gardner-Robertson scale (good-serviceable, pure tone average 0-50 dB, speech discrimination 50-100%)

The efficacy of radiosurgery using the Gamma Knife in the comprehensive analysis of data from 28 papers ([Table 2](#T0002){ref-type="table"}) was compared with several meta-analyses contained in the scientific literature \[[@CIT0001], [@CIT0059]--[@CIT0066]\] ([Table 3](#T0003){ref-type="table"}). Age of patients ranged on average from 51.8 to 57 years \[[@CIT0064], [@CIT0060]\]. Tumor size presented in units of volume ranged from 2.7 to 4.0 cm^3^. With an observation period from 16 to over 60 months, tumor growth inhibition was achieved in an average of 81 to 100% of patients, and the preservation of serviceable hearing from 20 to 57% of such patients.

###### 

Data from review papers

  First author, year \[references\]   Years of cited publications   Number of patients   Age of patients   Tumor volume (cm^3^)   Marginal dose (Gy)   Mean follow-up (months)   Tumor control (%)   Hearing preser-vation (%)
  ----------------------------------- ----------------------------- -------------------- ----------------- ---------------------- -------------------- ------------------------- ------------------- ---------------------------
  Myrseth, 2007 \[[@CIT0037]\]        1989--2006                    300                                                                                                                              
  Rowe, 2007 \[[@CIT0050]\]           1984--2005                    856                  57                2.8                    13.0                 45.0                                          
  Sughrue, 2009 \[[@CIT0053]\]        1979--2007                    50 000                                 \< 25 mm               \> 13; \< 13                                                       
  Yang, 2009 \[[@CIT0062]\]           1990--2007                    1908                 55.3              3.2                    13.1                 54.1                      82.5                
  Yang, 2009 \[[@CIT0061]\]           1988--2007                    2083                 53.6              4.05                   16                   41.2                      94                  57
  Yang, 2010 \[[@CIT0063]\]           1998--2007                    4 234                51.8              3.9                    14.2                 44.4                      92.0                51.0
  Arthurs, 2011 \[[@CIT0002]\]        2004--2009                    397--5825                              2.7--4.0               13.7--17.3           25--60                    91--94.6            44--57
  Murphy, 2011 \[[@CIT0036]\]         1992--2010                    29--162                                \< 3--3.14             8--25                16-- \> 60                81--100             20--51
  Whitmore, 2011 \[[@CIT0059]\]       1990--2008                                                                                                                                                     

Empty data fields are from data that were not reported.

A comparison of the results of the analysis made on the basis of papers published in the period 1998--2007 \[[@CIT0064]\] with the analysis of the current series of works from the period 2007--2011 shows that both of these series combine the highest similarity in the type of data obtained. Based on surveys, it was found that data on patient age, tumor size and tumor growth control are not significantly different between the several sets of analyses ([Table 4](#T0004){ref-type="table"}). There was, however, a highly significant difference in the size of the dose and in the degree of serviceable hearing preservation, and quite significant in the follow-up ([Fig. 1](#F0001){ref-type="fig"}, [2](#F0002){ref-type="fig"} and [3](#F0003){ref-type="fig"}). In the current series of studies, the dose applied to the periphery of the tumor was lower, the hearing preservation was higher, and the follow-up was longer than in previous series \[[@CIT0064]\].

![Marginal dose in the earlier (1) \[[@CIT0063]\] and current (2) series of studies -- significance of differentiation in [Table 4](#T0004){ref-type="table"}](WO-18-22073-g001){#F0001}

![Hearing preservation in the earlier (1) \[[@CIT0063]\] and current (2) series of studies -- significance of differentiation in [Table 4](#T0004){ref-type="table"}](WO-18-22073-g002){#F0002}

![Follow-up in the earlier (1) \[[@CIT0063]\] and current (2) series of studies -- significance of differentiation in [Table 4](#T0004){ref-type="table"}](WO-18-22073-g003){#F0003}

###### 

Comparison of data from earlier studies \[[@CIT0063]\] and current series -- results of variance analysis -- *p*-value[\*](#TF0004){ref-type="table-fn"}

  Kind of statistical test           Number of patients   Age of patients   Tumor volume   Marginal dose (Gy)   Follow-up    Tumor control rate   Hearing preservation
  ---------------------------------- -------------------- ----------------- -------------- -------------------- ------------ -------------------- ----------------------
  Kruskal-Wallis Test                0.2480               0.5462            0.3461         **0.0009**           **0.0398**   0.2614               **0.0166**
  Pr \> χ^2^                                                                                                                                      
  Median One-Way Analysis            0.3369               0.1662            0.1055         **0.0006**           0.0906       0.7078               **0.0157**
  Pr \> χ^2^                                                                                                                                      
  Van der Waerden One-Way Analysis   0.1980               0.5976            0.4688         **0.0010**           0.0736       0.2099               **0.0259**
  Pr \> χ^2^                                                                                                                                      
  Kolmogorov-Smirnov                 0.4509               0.7154            0.1312         **0.0086**           0.0889       0.6079               **0.0382**
  Two-Sample Test Pr \> KSa                                                                                                                       

Significance at p \< 0.05

Discussion {#S0004}
==========

The most important goal in treating patients with vestibular schwannoma is the control of tumor growth and maintaining the quality of life (QOL), while minimizing the side effects of treatment. Gamma Knife generally meets these criteria and is used successfully worldwide as an alternative method of treatment of VS \[[@CIT0050]\]. The use of the Gamma Knife in radiosurgery of vestibular schwannoma is a breakthrough for patients suffering from this disease. In most cases, it does not create a need for hospitalization \[[@CIT0063], [@CIT0064]\]. The results of many years of experience, gained in leading medical institutions, have led to improvements of GK \[[@CIT0005], [@CIT0006]\]. The latest model, LGK PFX, is more widely used, most recently in Russia and Ukraine \[[@CIT0004]\]. Implementation of a quantitative comparison of radiosurgical treatment of VSs using the Leksell Gamma Knife Perfexion and Model C has shown that the most important new features of PFX lead to improvement of dosimetric parameters, especially for large tumors \[[@CIT0042]\]. Optimizing the dose planning can improve results of treatment, but a fully comprehensive assessment of the benefits to patients requires long-term clinical observations.

In numerous studies on the use of Gamma Knife radiosurgery for vestibular schwannomas, there are many factors that have been frequently studied in detail \[[@CIT0007]--[@CIT0052]\]. These include patient age, tumor size, dose to the tumor periphery, tumor growth control, the preservation of hearing and facial nerve function, and the quality of life after radiosurgery. To analyze the preservation of hearing, most neuro-laryngology reports use the classification of AAO-HNS and the majority of neurosurgical publications apply the GR classification \[[@CIT0017]\]. Differences between pre- and postoperative hearing class are presented differently in each survey. A common strategy is, however, the use of the concept of serviceable hearing (GR grade I or II or the AAO-HNS class A or B). Such a strategy was adopted in this work.

The results of a systematic study by Yang and colleagues show that the radiation dose is an important and critical prognostic factor for hearing preservation regardless of tumor size or age of patients with VS treated with GKRS \[[@CIT0063]\]. Patients treated with doses ≤ 13 Gy had better hearing compared to patients treated with high doses. Results of treatment of hearing loss in older patients were comparable to the results of younger patients. Similarly, patients with large tumors had clinical indicators of serviceable hearing loss compared to patients with small tumors. This suggests that patient age and tumor size may not be critical prognostic factors in predicting the preservation of hearing after GKRS. The analysis presented in this study, conducted on the basis of the results documented in the literature of the last five years, points to the patients' age and tumor size being less critical in predicting preservation of hearing. Highly important, however, was the application of the lower radiation dose to the periphery of the tumor used in recent years, thanks to the introduction into medical centers of the new models of GK and greater possibilities of precise planning.

The results of a comprehensive analysis of facial nerve preservation after radiosurgery of VS using GK confirmed the importance of medium doses of radiation as an important and critical prognostic factor \[[@CIT0062]\]. In this case, however, the patient\'s age played a significant role. In patients treated with 13 Gy or less, with tumors smaller than 1.5 cm^3^ in volume, results of treatment in young patients were better than in older patients. According to Kim *et al*. \[[@CIT0006]\] to reduce the radiation dose, however, does not adequately protect the hearing, and therefore it is believed that this is a more complicated problem and requires further study. Common hypotheses for hearing deterioration after irradiation include damage to cochlear primary sensory cells, injury to the cochlear nerve by the tumor, injury to the cochlear nerve by radiation, and compression or vascular thrombosis, leading to ischemic injury of the cochlea \[[@CIT0025]\]. Franzin \[[@CIT0022]\] believes that due to the high frequency of hearing loss in patients prior to radiosurgery, it is difficult to determine whether hearing loss is caused by the surgery or the natural course of the disease. The exact mechanism of delayed hearing loss is still unclear.

Preservation of hearing in patients is associated with the overall quality of life (QOL). Whitmore *et al*. \[[@CIT0065]\] compared the quality of life in patients after 5 years of radiosurgical and surgical treatment. Overall QOL was better when patients were treated with radiosurgery, but too little information on QOL after 10 years did not allow this thesis to be proved in the long run. There is a need for further research in this field \[[@CIT0059]\].

In conclusion, clinical findings widely documented in the literature over the past five years indicate the progress in treatment of vestibular schwannoma using Gamma Knife radiosurgery. In a new series of studies, published in 2007--2011, the average dose applied to the periphery of the tumor was lower (12.4 Gy) than in the earlier series from the years 1998 to 2007 (14.2 Gy), and hearing preservation was higher (66.45% vs. 51.0%). This was confirmed statistically, and the differences were highly significant.
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